Novel therapeutic targets in diffuse large B-cell lymphoma

European Journal of Cancer, Supplement

Volumn 11, Issue 2, 2013, Pages 262-263

  Lenz, Georg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BRUTON TYROSINE KINASE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRUTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

BIODIVERSITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; LARGE CELL LYMPHOMA; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 84884953741     PISSN: 13596349     EISSN: 18781217     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2013.07.041     Document Type: Review

References (14)

1. Nogai H., Dorken B., Lenz G. Pathogenesis of Non-Hodgkin's lymphoma. J Clin Oncol 2011, 29:1803-1811.
2. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
3. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
4. Lenz G., Wright G.W., Emre N.C., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008, 105:13520-13525.
5. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
6. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity Is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194:1861-1874.
7. Lenz G., Davis R.E., Ngo V.N., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
8. Compagno M., Lim W.K., Grunn A., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
9. Davis R.E., Ngo V.N., Lenz G., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
10. Ngo V.N., Young R.M., Schmitz R., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
11. Dunleavy K., Pittaluga S., Czuczman M.S., et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009, 113:6069-6076.
12. Wilson W., Gerecitano J., Goy A., et al. The Bruton's tyrosine kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 2012, [ASH Abstract 623].
13. Cerchietti L.C., Yang S.N., Shaknovich R., et al. A peptomimetic inhibitor of BCL6 with potent anti-lymphoma effects in vitro and in vivo. Blood 2009, 113:3397-3405.
14. Cerchietti L.C., Ghetu A.F., Zhu X., et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010, 17:400-411.